Clinical Edge Journal Scan

TARE may substitute surgical resection for initial treatment of large single nodular HCC


 

Key clinical point : The better safety profile of transarterial radioembolization (TARE) together with comparable efficacy makes it a potential therapeutic alternative to surgical resection for large single nodular hepatocellular carcinoma (HCC).

Main finding: After inverse probability weighting, TARE vs surgical resection achieved similar overall survival (hazard ratio [HR], 0.98; P = .97), time to progression (HR, 1.10; P = .80), and time to intrahepatic progression (HR, 1.45; P = .30), along with a shorter hospital stay (3 days vs 12 days; P < .001) and lower patient proportion experiencing adverse events requiring intervention (0.0% vs 3.2%; P = .39).

Study details: Findings are from a retrospective cohort study including 557 adult patients with single nodular HCC measuring 5 cm who underwent either surgical resection (n=500) or TARE (n=57) shortly after diagnosis.

Disclosures: The authors reported no source of funding. Some of the authors received lecture fees or research grants from various sources.

Source: Kim J et al. J Nucl Med. 2021 Dec 9. doi: 10.2967/jnumed.121.263147 .

Recommended Reading

Reduction hepatectomy plus multidisciplinary therapy improves HCC outcomes
Federal Practitioner
Transarterial chemoembolization plus percutaneous microwave ablation optimizes outcomes for unresectable HCC
Federal Practitioner
Lenvatinib tops sorafenib for progression-free survival in HCC
Federal Practitioner
Clinical Edge Journal Scan Commentary: HCC December 2021
Federal Practitioner
No survival benefits with first-line nivolumab vs sorafenib in advanced HCC
Federal Practitioner
Atezolizumab + bevacizumab shows long-term benefits over sorafenib for unresectable HCC
Federal Practitioner
HAIC-FO outperforms sorafenib against advanced HCC in phase 3
Federal Practitioner
Radiologic response to TACE-RT as a prognostic factor in advanced HCC with macroscopic vascular invasion
Federal Practitioner
Whole blood viscosity as a biomarker for distant metastasis and survival in HCC
Federal Practitioner
Utilization of AFP to predict HCC recurrence after liver transplantation in waitlisted patients
Federal Practitioner